<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388635</url>
  </required_header>
  <id_info>
    <org_study_id>PET-VEL-2004-01</org_study_id>
    <nct_id>NCT00388635</nct_id>
  </id_info>
  <brief_title>Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.</brief_title>
  <official_title>A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <brief_summary>
    <textblock>
      This protocol is planned as a multicentric, national, open-label trial designed to evaluate,
      first, optimal dose of Velcade® (Bortezomib) in combination with melphalan and prednisone.
      After optimal dose is known, the second aim is evaluate safety and tolerance of V-MP plan, in
      respond terms, in a cohort of 60 patients. Finally, the entire results will be compared with
      those obtained from a series of 100 patients, all of them over 70 years old, diagnosed of
      Multiple Myeloma belonging to the GEM protocol finished in May 2003
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Myeloma is a neoplastic disorder of the last maturation stage of B cell, called
      plasmatic cell. It represents the second most common haematological neoplasia, after Non
      Hodgkin Lymphoma. The annual incidence is over 4 cases per 100.000. Multiple Myeloma is an
      invariably mortal disease. When illness advances, the reduction of infections resistance, the
      intense bones destruction (with bone pain, pathological fractures and hypercalcemia),
      anaemia, renal failure and, in a less frequency, neurological complications and
      hyperviscosity provoke severe morbidity and mortality. Five-year survival rate in patients
      with Multiple Myeloma treated with conventional chemotherapy is 29%. There is an urgent need
      of new therapeutic agents for the treatment of this disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determinate the efficacy of combination velcade, melphalan, prednisone</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess potential superiority of this regimen versus historical controls with melphalan and prednisone alone</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate efficacy in terms of progression-free survival and overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is, in the investigator's opinion, willing and able to comply with the
             protocol requirements.

          -  Patient has given voluntary written informed consent before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to their future
             medical care.

          -  Age over 65 years.

          -  Patient recently diagnosed with symptomatic Multiple Myeloma based on standard
             criteria and that has not received any previous chemotherapy treatment for Multiple
             Myeloma.

          -  Patient has measurable disease, defined as follows:

        For secretory multiple myeloma, measurable disease is defined as any quantifiable serum
        monoclonal protein value and, where applicable, urine light-chain excretion of ≥ 200 mg/24
        hours.

        For oligo or non-secretory multiple myeloma, measurable disease is defined by the presence
        of soft tissue (not bone) plasmacytomas as determined by clinical examination or applicable
        radiographs (i.e. MRI, CT-Scan). In patients with oligo-secretory multiple myeloma, the
        serum and/or urine M-protein measurements are very low and difficult to follow for response
        assessment. In patients with non-secretory multiple myeloma, there is no M-protein in serum
        or urine.

          -  Patient has a Karnofsky performance status higher 60%.

          -  Patient has a life-expectancy &gt;3 months.

          -  Patient has the following laboratory values within 14 days before Baseline visit (Day
             1 of Cycle 1, before study drug administration:

        Platelet count ≥ 100x109/L, hemoglobin ≥ 8 g/dl and absolute neutrophil count (ANC) ≥
        1.0x109/L.

        Corrected serum calcium &lt; 14mg/dl. Aspartate transaminase (AST): ≤ 2.5 x the upper limit of
        normal. Alanine transaminase (ALT): ): ≤ 2.5 x the upper limit of normal. Total bilirubin:
        ≤1.5 x the upper limit of normal. Serum creatinine value ≤ 2mg/dl.

        Exclusion Criteria:

          -  Patient previously received treatment with Velcade.

          -  Patient previously received treatment for Multiple Myeloma.

          -  Patient had major surgery within 4 weeks before enrollment.

          -  Patient has a platelet count &lt; 100 x 109/L within 14 days before enrollment.

          -  Patient has an absolute neutrophil count &lt; 1.0 x 109/L within 14 days before.

          -  Patient has &lt; Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Patient has received other investigational drugs within 14 days before enrollment.

          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV),
             Hepatitis B surface antigen-positive or active hepatitis C infection.

          -  Patient had a myocardial infarction within 6 months of enrollment or has New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

        Patient is enrolled in another clinical research study and/or is receiving an
        investigational agent for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>San Miguel Jesús, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Blanca de León</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <reference>
    <citation>Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33.</citation>
    <PMID>10735013</PMID>
  </reference>
  <reference>
    <citation>2. Longo D. Plasma cell disorders. In : Fauce A, et al. Ed. Harrison's Principles of Internal Medicine. 14th Ed. New York, New York: Mc Graw-Hill; 1998: 712-718</citation>
  </reference>
  <reference>
    <citation>Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med. 1999 Nov 18;341(21):1606-9.</citation>
    <PMID>10564693</PMID>
  </reference>
  <reference>
    <citation>Oken MM. Management of Myeloma: Current and Future Approaches. Cancer Control. 1998 May;5(3):218-225.</citation>
    <PMID>10761055</PMID>
  </reference>
  <reference>
    <citation>Westin J. Conventional chemotherapy in multiple myeloma. Pathol Biol (Paris). 1999 Feb;47(2):169-71.</citation>
    <PMID>10192883</PMID>
  </reference>
  <reference>
    <citation>Huang YW, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R. Current drug therapy for multiple myeloma. Drugs. 1999 Apr;57(4):485-506. Review.</citation>
    <PMID>10235689</PMID>
  </reference>
  <reference>
    <citation>Smith ML, Newland AC. Treatment of myeloma. QJM. 1999 Jan;92(1):11-4. Review.</citation>
    <PMID>10209667</PMID>
  </reference>
  <reference>
    <citation>Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997 Jun 5;336(23):1657-64. Review.</citation>
    <PMID>9171069</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994 Feb 17;330(7):484-9. Review.</citation>
    <PMID>8289856</PMID>
  </reference>
  <reference>
    <citation>Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992 Feb;10(2):334-42.</citation>
    <PMID>1531068</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990 Feb;33(2):86-9.</citation>
    <PMID>2301376</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992 Aug 15;80(4):887-90.</citation>
    <PMID>1498331</PMID>
  </reference>
  <reference>
    <citation>Case DC Jr, Lee DJ 3rd, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897-903.</citation>
    <PMID>605911</PMID>
  </reference>
  <reference>
    <citation>Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7.</citation>
    <PMID>8649495</PMID>
  </reference>
  <reference>
    <citation>Driscoll J. The role of the proteasome in cellular protein degradation. Histol Histopathol. 1994 Jan;9(1):197-202. Review.</citation>
    <PMID>8003815</PMID>
  </reference>
  <reference>
    <citation>Richter-Ruoff B, Wolf DH. Proteasome and cell cycle. Evidence for a regulatory role of the protease on mitotic cyclins in yeast. FEBS Lett. 1993 Dec 20;336(1):34-6.</citation>
    <PMID>8262212</PMID>
  </reference>
  <reference>
    <citation>Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol. 1995 Aug;2(8):503-8. Review.</citation>
    <PMID>9383453</PMID>
  </reference>
  <reference>
    <citation>Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 1;61(7):3071-6.</citation>
    <PMID>11306489</PMID>
  </reference>
  <reference>
    <citation>Sherr CJ. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672-7. Review.</citation>
    <PMID>8939849</PMID>
  </reference>
  <reference>
    <citation>Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 1999 May 14;97(4):431-4. Review.</citation>
    <PMID>10338207</PMID>
  </reference>
  <reference>
    <citation>Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995 May;2(5):493-506.</citation>
    <PMID>7538441</PMID>
  </reference>
  <reference>
    <citation>Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773-85.</citation>
    <PMID>8087845</PMID>
  </reference>
  <reference>
    <citation>Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug;4(4):219-29. Review.</citation>
    <PMID>8400144</PMID>
  </reference>
  <reference>
    <citation>Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996 Nov 1;274(5288):782-4.</citation>
    <PMID>8864118</PMID>
  </reference>
  <reference>
    <citation>Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001 Feb;107(3):241-6. Review.</citation>
    <PMID>11160144</PMID>
  </reference>
  <reference>
    <citation>26. McConkey DJ, Pettaway C, Elliott P, et al. The proteasome as a new drug target in metastatic prostate cancer. ATMDACC 7th Annual Genitourinary Oncology Conference, 1998</citation>
  </reference>
  <reference>
    <citation>Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.</citation>
    <PMID>10363983</PMID>
  </reference>
  <reference>
    <citation>28. Millenium Pharmaceuticals, Inc. (PS-341) Investigator's Brochure, Version 5.0, 2001</citation>
  </reference>
  <reference>
    <citation>Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.</citation>
    <PMID>12826635</PMID>
  </reference>
  <reference>
    <citation>Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 2003 Jul 1;102(1):69-77. Epub 2003 Mar 13.</citation>
    <PMID>12637329</PMID>
  </reference>
  <reference>
    <citation>Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13.</citation>
    <PMID>16840727</PMID>
  </reference>
  <reference>
    <citation>Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.</citation>
    <PMID>9753033</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <last_update_submitted>January 8, 2011</last_update_submitted>
  <last_update_submitted_qc>January 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>pethema</name_title>
    <organization>pethema</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Patients over 65 years old</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

